Repare Therapeutics Inc. was a clinical-stage precision oncology company whose updates centered on oncology drug programs, portfolio partnerships, and corporate-status developments. Recurring news included clinical disclosures for RP-1664, an oral PLK4 inhibitor studied in TRIM37-high solid tumors in the LIONS trial, and RP-3467, a Polθ ATPase inhibitor evaluated in the POLAR trial. Other updates covered the lunresertib PKMYT1 inhibitor license, out-licensing of discovery platforms, operating results, capital-structure matters, governance, and the completed acquisition and related delisting process.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.